Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What’s A "Complete" Application? Clarity From FDA Could Speed Review Times

Executive Summary

A clarification of what constitutes a complete application likely will be included in a package of review process changes expected in the Prescription Drug User Fee Act reauthorization.

You may also be interested in...



ANDA Backlog Withdrawals May Stimulate Secondary Market By Foreign Firms

Applications removed from the backlog to avoid GDUFA charge may generate interest from sponsors looking to gain quicker entry into the U.S. market, but work likely would still be required to gain approval.

Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model

NMEs and novel biologics will see reviews allotted two additional months under the revised model launching Oct. 1. Industry expects to gain more communication and first-cycle approvals, while FDA hopes it can receive more complete applications at submission and improve transparency.

PDUFA V: FDA Application Completeness Crackdown Continues

FDA remains firm in its push for application completeness in PDUFA V, despite its willingness to add two new review cycle meetings with sponsors.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel